Summary
Other Scenarios:
- PG - XOM
- PG - GE
- XOM - BF
- GE - BF
| Buyer: | The Procter & Gamble Company (PG) | Last Price: | 67.81 | Market Cap.: | 211.30B |
|---|---|---|---|---|---|
| Target: | BASF AG (ADR) (BF) | Last Price: | 129.52 | Market Cap.: | 63.53B |
Lines of Business Summary:
- The Procter & Gamble Company (PG) competes in 3 industries and 55 product/service groups
- BASF AG (ADR) (BF) competes in 4 industries and 24 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- The Procter & Gamble Company (PG) has 10 and BASF AG (ADR) (BF) has 2 suppliers that rely on a material % of their business. They share 0 in common.
- The Procter & Gamble Company (PG) has 1 and BASF AG (ADR) (BF) has 0 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
930 |
|
*Media |
|
148 | |
|
Energy |
|
358 | |
|
Manufacturing |
|
|
1,192 |
|
Retail and Wholesale |
|
283 |
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 75)
|
Target (Total: 6)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 64)
|
Target (Total: 24)
|
Buyer (Total: 10)
|
Target (Total: 14)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 138,000 | 94,708 |
| Revenue Per Employee | 560,143.3 | 856,687.1 |
| Total Revenue | 19,272.0 | 20,214.3 |
| Total Expenses | 15,872.0 | 17,446.2 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
9,477.0 | 14,508.4 |
|
SG&A Expense
|
6,395.0 | 2,290.9 |
|
Research & Development
|
0.0 | 464.8 |
|
Other Operating Expense
|
0.0 | 182.1 |
|
Operating Income
|
3,400.0 | 2,768.2 |
|
Unusual Income
|
0.0 | 0.0 |
|
LT Debt to Capital
|
25.93 | 25.84 |
|
Fwd P/E
|
19.44 | n/a |
|
Fwd P/Rev
|
2.59 | n/a |
| Book Value | 65,354.0 | 26,592.0 |
|
Curr Portion of LTD/Cap Lease
|
12,039.0 | 4,526.7 |
Individual Company Summary
Focused
Buyer
Focused ():
Manufacturing > Consumer Manufacturing > Personal Care and Cleaning Products
Target
Focused ():
Manufacturing > Materials > Chemicals
Business Description
Buyer
The Procter & Gamble Company (P&G) is focused on providing branded consumer goods products. The Company markets its products in more than 180 countries. During the fiscal year ended June 30, 2007 (fiscal 2007), the Company was organized into three global business units: Beauty and Health, Household Care and Gillette GBU. P&G had seven segments under United States Generally Accepted Accounting Principles: Beauty; Health Care; Fabric Care and Home Care; Snacks, Coffee and Pet Care; Baby Care and Family Care; Blades and Razors, and Duracell and Braun. In September 2006, the Company's Sure brand (an antiperspirant and deodorant brand) was acquired by Innovative Brands, LLC. In January 2007, P&G acquired HDS Cosmetics Lab Inc., which manufactures and markets Doctor's Dermatologic Formula (DDF) skin care.
Target
BASF Aktiengesellschaft (BASF) is a transnational chemical company that comprises the parent company, BASF Aktiengesellschaft of Ludwigshafen, Germany, and 327 consolidated subsidiaries. The Company operates more than 150 production sites. BASF has five business segments: Chemicals, Plastics, Performance Products, Agricultural Products & Nutrition, and Oil & Gas. These business segments encompass BASF?s 14 operating divisions. On December 13, 2006, the Company acquired PEMEAS GmbH. On July 1, 2006, it acquired the construction chemicals business of Degussa AG. On July 1, 2006, BASF acquired Johnson Polymer from JohnsonDiversey, Inc. On June 26, 2006, it acquired CropDesign N.V. On June 6, 2006, BASF acquired Engelhard Corp. On November 27, 2006, the Company divested its global terbufos insecticide business to AMVAC Chemical Corporation. On March 31, 2006, BASF sold major parts of its Micro Flo generic agrochemical business in the United States to Arysta LifeScience.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
52.03 | 28.1 |
|
Operating Margin %
|
20.2 | 12.48 |
|
Quick Ratio
|
0.4 | 0.93 |
|
Current Ratio
|
0.78 | 1.41 |
|
Coverage Ratio
|
-0.08 | -0.07 |
| Total Assets | 138,014.0 | 64,567.0 |
| Return on Equity % | 15.49 | 19.22 |
| Return on Assets % | 7.49 | 7.92 |
|
Cash+ ST Inv. Per Share
|
1.65 | 2.28 |
| Total Debt | 35,414.0 | 13,875.3 |
| Total Debt to Equity % | 53.05 | 52.18 |
| Total Debt to Tangible Equity % | n/a | 94.17 |
|
Debt to Asset %
|
25.66 | 21.49 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Scientific Products |
|
|
|
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television, Film and Video
Companies involved in the production, post-production, and distribution of Motion Pictures and Television programming.
|
|
|
|
Energy |
|
|
|
Upstream |
|
|
|
Crude Oil and Natural Gas Exploration/Production
Companies that engage in exploration and production of crude oil and natural gas from land or sea oilfields.
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
|
|
|
|
Household Products
The Household Products sector includes furniture and other home and institutional decorative items, major and small appliances, kitchenware, and other related products.
|
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Materials |
|
|
|
Chemicals
The Chemicals Subsector includes companies that manufacture basic, intermediate, specialty, and performance chemicals.
|
|
|
|
Retail and Wholesale |
|
|
|
Industrial Equipment and Supplies |
|
|
|
Machinery, Equipment and Supplies
Wholesalers and dealers of machinery, equipment, and supplies used in construction, mining, farming, transportation and other industrial sectors. Companies that rent similar types of equipment are also included.
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Upper Respiratory |
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Arrhythmia |
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics that treat peptic ulcers by preventing the secretion of acid as well as treating infections by using antibiotics.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antisecretory Agents
Therapeutics that treat diarrhea by bringing fluid movement within the intestine to normal levels.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, and causing the shedding of the horny layer of the skin by modulating cell differentiation and proliferation.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Heliobacter pylori |
|
|
|
Antisecretory Agents/Nitroimidazoles/Tetracyclines
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Heterotopic Ossification |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat ossification by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Osteoporosis |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat spasticity by preventing the release of calcium from the sarcoplasmic reticulum which results in reduced involuntary muscle contractions.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Sexual Dysfunction |
|
|
|
Androgens
Therapeutics that treat female sexual dysfunction by providing male sex hormone, such as testosterone, that is important for the normal functioning of the female reproductive system.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Amphetamines
Therapeutics that treat coughs and colds by helping to relieve nasal congestion.
Buyer Products:
|
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Buyer Products:
|
|
|
|
Expectorants/Opioids
Therapeutics that treat coughs and colds by suppressing the cough and helping in the ejection of the mucous.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Hyperthermia |
|
|
|
Calcium Channel Inhibitors
Therapeutics that treat hyperthermia by preventing the release of calcium from the sarcoplasmic reticulum which results in inhibits the catabolic processes responsible for increase in temperature.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies |
|
|
|
Diagnostic |
|
|
|
Temperature |
|
|
|
Thermometers
Medical instruments designed to measure the temperature in patients
Buyer Products:
|
|
|
|
Orthopedics |
|
|
|
Treatment |
|
|
|
Pain Management |
|
|
|
General Purpose |
|
|
|
Dry Heat Therapy
Devices that control the of use dry heat to ease pain associated with musculoskeletal injuries.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Nutritional Supplements
Contract Manufacturing Organizations that manufacture nutritional supplements for other organizations.
Target Products:
|
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Consumables |
|
|
|
Bioanalytical Chemistry |
|
|
|
Cell Biology |
|
|
|
Cell Proliferation |
|
|
|
Kits
Cell proliferation consumables that are a collection of reagents, standards, and other consumables assembled for used in various biological analyses.
Buyer Products:
|
|
|
|
*Media |
|
|
|
Entertainment/Programming |
|
|
|
Television, Film and Video |
|
|
|
Production |
|
|
|
Television |
|
|
|
Domestic |
|
|
|
Soap Opera
Shows depicting the interconnected lives of many characters often in a sentimental, melodramatic way.
Buyer Products:
|
|
|
|
Energy |
|
|
|
Upstream |
|
|
|
Crude Oil and Natural Gas Exploration/Production |
|
|
|
Americas |
|
|
|
Latin America
Companies that engage in Oil/Gas exploration and production in Latin America.
Target Products:
|
|
|
|
Europe |
|
|
|
North Sea
Exploration, extraction, and production of crude oil and natural gas from offshore oilfields located in the North Sea. Norway has the largest single reserves in this region, followed by the Untied Kingdom. Germany, Denmark, and the Netherlands possess smaller fields here.
Target Products:
|
|
|
|
Other Europe
Exploration, extraction, and production of crude oil and natural gas from oilfields located in other regions of Europe.
Target Products:
|
|
|
|
Middle East/Africa
Companies that engage in Oil/Gas exploration and production in the Middle East/Africa region.
Target Products:
|
|
|
|
Russia/CIS/FSU
Companies that engage in Oil/Gas exploration and production in Russia and the CIS (Commonwealth of Independent States) or the Former Soviet Union (FSU). Includes Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.
Target Products:
|
|
|
|
Manufacturing |
|
|
|
Consumer Manufacturing |
|
|
|
Food, Beverage and Agriculture |
|
|
|
Beverages |
|
|
|
Non-Alcoholic Beverages |
|
|
|
Coffee/Tea
Coffee and Tea Manufacturing.
Buyer Products:
|
|
|
|
Food |
|
|
|
Pet Food
Food for dogs and cats.
Buyer Products:
|
|
|
|
Sweets/Snacks |
|
|
|
Snack Foods
Manufacturers of Potato Chips, Peanuts, Trail Mix, and Cheese Snacks.
Buyer Products:
|
|
|
|
Household Products |
|
|
|
Household Appliances and Tools |
|
|
|
Other Household Products |
|
|
|
Brooms, Brushes, and Mops
Brooms, brushes, mops, and other manual cleaning equipment.
Buyer Products:
|
|
|
|
Small Electrical Appliances/Accessories |
|
|
|
Consumer Batteries
Relatively small, portable batteries used to power all varieties of consumer electronic devices. These one-time-use or rechargeable batteries store electric energy and can be used to power various devices ranging from CD players to cell phones. The most popular battery types include: lithium (Li), lithium ion (Li-ion), nickel-metal hybrid (NiMH), and nickel-cadmium (NiCAD). Flashlights are included at this level.
Buyer Products:
|
|
|
|
Kitchen/Bath Appliances
Electrical Kitchen/Bath Appliances, including toasters; juicemakers; and food blenders, as well as electrical toothbrushes, hairdryers, and electric massagers.
Buyer Products:
|
|
|
|
Personal Care and Cleaning Products |
|
|
|
Absorbent Products
Absorbent products, including tampons, pads, and diapers.
Buyer Products:
|
|
|
|
Anti-Perspirant
Anti-Perspirant and/or deodorant.
Buyer Products:
|
|
|
|
Cosmetics
Companies engaged in the manufacturing of cosmetics, such as lipstick, powders, and other make-up.
Buyer Products:
|
|
|
|
Fragrances
Companies engaged in the manufacturing of fragrances, such as perfume and cologne.
Buyer Products:
|
|
|
|
Hair Care
Companies engaged in the manufacturing of hair care products, such as shampoo, conditioner, hair dye, hair spray, styling gel, and mousse. Also includes hair accessories, such as pins, clips, and curlers.
Buyer Products:
|
|
|
|
Household Cleaning Products
Chemical-based household cleaning products, such as detergent and surface cleaner. Also includes automotive cleaning products.
Buyer Products:
|
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Sanitary/Personal Care Paper
Companies engaged in the manufacturing of sanitary/personal care paper such as napkins and tissues.
Buyer Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Soap/Body Wash
Soap, Body Wash, and Shower Gel.
Buyer Products:
|
|
|
|
Materials |
|
|
|
Chemicals |
|
|
|
Basic and Intermediate Chemicals |
|
|
|
Dyes and Pigments
Includes companies engaged in the manufacturing of dyes and pigments.
Target Products:
|
|
|
|
Inorganic Chemicals |
|
|
|
Chlor-alkalies
Includes companies engaged in the manufacturing of chlor-alkalies, such as caustic soda, chlorine, soda ash and others.
Target Products:
|
|
|
|
Other Inorganic Chemicals
Includes companies engaged in the manufacturing of basic and intermediate inorganic chemicals, such as compounds of ammonium, chromium, potassium, sodium, sulfur, nitrogen, and others.
Target Products:
|
|
|
|
Petrochemicals and Other Organic Chemicals |
|
|
|
Other Organic Chemicals
Includes companies engaged in the manufacturing of other basic and intermediate organic chemicals, such as industrial alcohol, acrylate, vinyl chloride monomer, vinyl acetate monomer, formaldehyde, enzymes, proteins, fatty acids and others. Ethanol is excluded from this level.
Target Products:
|
|
|
|
Petrochemicals
Includes companies engaged in the manufacturing of petrochemicals, such as phenol, benzene, cumene, ethylene, propylene, xylene, butadiene, butylene, aniline and others.
Target Products:
|
|
|
|
Specialty and Performance Chemicals |
|
|
|
Additives |
|
|
|
Fuel Additives
Includes companies engaged in the manufacturing of fuel additives, chemicals added to fuels to impart specific beneficial properties or to enhance performance. Ethanol is excluded from this level.
Target Products:
|
|
|
|
Other Performance Additives
Includes companies engaged in the manufacturing of other performance additives, chemicals added to a variety of materials to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Polymer Additives
Includes companies engaged in the manufacturing of polymer additives, chemicals added to polymers to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Pulp and Paper Additives
Includes companies engaged in the manufacturing of pulp and paper additives, chemicals added to pulp and paper to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Adhesives, Sealants, Coatings and Paints |
|
|
|
Adhesives and Sealants |
|
|
|
Industrial Adhesives and Sealants
Includes companies engaged in the manufacturing of other industrial adhesives and sealants.
Target Products:
|
|
|
|
Coatings and Paints |
|
|
|
Coatings
Includes companies engaged in the manufacturing of coatings used in a wide range of industries.
Target Products:
|
|
|
|
Agrochemicals |
|
|
|
Pesticides
Includes companies engaged in the manufacturing of pesticides, such as herbicides, fungicides, insecticides, miticides, rodenticides, germicides, and others.
Target Products:
|
|
|
|
Cleaning and Sanitizing Agents |
|
|
|
Soaps and Detergents
Includes companies engaged in the manufacturing of soaps and detergents used in a wide range of industries.
Target Products:
|
|
|
|
Fibers and Polymers |
|
|
|
Other Fibers and Polymers
Includes companies engaged in the manufacturing of other fibers and polymers not classified as plastic or rubber.
Target Products:
|
|
|
|
Plastic Resins and Materials
Includes companies engaged in the manufacturing of plastic resins and materials, such as polyethylene, polypropylene, polystyrene, polycarbonates, thermoplastic polyester, polyamide, acrylonitrile butadiene styrene and others.
Target Products:
|
|
|
|
Other Specialty and Performance Chemicals |
|
|
|
Film and Imaging Chemicals
Includes companies engaged in the manufacturing of film and imaging chemicals.
Target Products:
|
|
|
|
Retail and Wholesale |
|
|
|
Industrial Equipment and Supplies |
|
|
|
Machinery, Equipment and Supplies |
|
|
|
MRO (Maintenance/Repair/Overhaul) Supplies Distributors
Distributors of MRO (Maintenance/Repair/Overhaul) Supplies, including machine tools, abrasives, adhesives, filters, lubricants, safety equipment, circuit breakers, transformers, switchboards, panelboards, busway and other similar items.
Target Products:
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Bayer AG (ADR)
|
|
n/a | 59,534.590 | 10.55 | 15.61 | 1.38 | 1.33 | n/a | |
|
Delphi Corporation
|
|
n/a | 317.407 | n/a | -0.23 | 0.01 | 0.01 | n/a | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 150,459.597 | 13.70 | 13.62 | 3.25 | 3.31 | 12.06 | |
|
PepsiCo, Inc.
|
|
n/a | 112,394.142 | 19.03 | 20.74 | 3.10 | 2.93 | 11.41 | |
| Target | |||||||||
|
Exxon Mobil Corporation
|
|
n/a | 491,787.026 | 12.21 | 12.73 | 1.31 | 1.34 | 4.23 | |
|
General Electric Company
|
|
n/a | 413,433.332 | 19.35 | 18.33 | 2.49 | 2.43 | 16.89 | |
|
Royal Dutch Shell plc (ADR)
|
|
n/a | 260,977.639 | 9.60 | n/a | 0.82 | n/a | 2.43 | |
|
TOTAL S.A. (ADR)
|
|
n/a | 175,823.241 | 11.48 | 11.03 | 0.99 | 0.94 | 3.27 | |
|
Eni S.p.A. (ADR)
|
|
n/a | 129,237.189 | 9.64 | 10.30 | 1.11 | 1.29 | 2.73 | |
|
E.ON AG (ADR)
|
|
n/a | 114,418.065 | 13.34 | 17.71 | 1.26 | 1.28 | 2.73 | |
|
Suez SA (ADR)
|
|
n/a | 68,365.996 | 15.06 | 15.29 | 1.07 | 1.02 | 23.17 | |
|
Bayer AG (ADR)
|
|
n/a | 59,534.590 | 10.55 | 15.61 | 1.38 | 1.33 | n/a | |
|
Norsk Hydro ASA (ADR)
|
|
n/a | 50,200.535 | 17.36 | 15.09 | 1.54 | 1.68 | 2.91 | |
|
E.I. du Pont de Nemours & Company
|
|
n/a | 44,222.181 | 13.52 | 15.20 | 1.48 | 1.50 | 7.13 | |
|
Honeywell International Inc.
|
|
n/a | 42,239.463 | 18.67 | 17.87 | 1.29 | 1.24 | n/a | |
|
Monsanto Company
|
|
n/a | 40,091.382 | 37.86 | 39.55 | 4.78 | 4.67 | 7.64 | |
|
The Dow Chemical Company
|
|
n/a | 39,883.473 | 11.40 | 10.85 | 0.79 | 0.79 | 2.73 | |
|
Sasol Limited (ADR)
|
|
n/a | 26,533.487 | 17.30 | 10.67 | 2.72 | 2.03 | 3.37 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 21,566.702 | 14.93 | 14.86 | 1.32 | 1.49 | 4.63 | |
|
Archer Daniels Midland Company
|
|
n/a | 20,826.413 | 9.63 | 12.03 | 0.47 | 0.46 | 1.90 | |
|
Syngenta AG (ADR)
|
|
n/a | 19,636.847 | 30.12 | 19.51 | 2.30 | 2.21 | 5.48 | |
|
Air Products & Chemicals, Inc.
|
|
n/a | 19,074.970 | 21.89 | 20.37 | 1.93 | 1.89 | 4.73 | |
|
Imperial Chemical Industries PLC (ADR)
|
|
n/a | 15,389.065 | 29.05 | n/a | 1.58 | n/a | n/a | |
|
PPG Industries, Inc.
|
|
n/a | 12,113.599 | 17.56 | 14.05 | 1.04 | 1.03 | 5.84 | |
|
Lyondell Chemical Company
|
|
n/a | 11,633.268 | n/a | 14.43 | 0.46 | 0.45 | 5.94 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Huntsman Corporation
|
|
n/a | 5,803.213 | n/a | 19.75 | 0.58 | 0.60 | 3.97 | |
|
Aspen Technology, Inc.
|
|
n/a | 1,246.431 | 47.13 | 20.10 | 3.89 | 3.77 | 14.40 | |
|
Salary.com, Inc.
|
|
n/a | 177.236 | n/a | -19.34 | 6.97 | 5.10 | 7.10 | |
|
Insightful Corporation
|
|
n/a | 26.515 | n/a | n/a | 1.06 | n/a | 3.00 | |
| Buyer | |||||||||
|
Nastech Pharmaceutical Co. Inc.
|
|
77.00% | 352.738 | n/a | -7.39 | 17.45 | 16.42 | 5.56 | |
|
Alexion Pharmaceuticals, Inc.
|
|
37.70% | 2,293.244 | n/a | -20.03 | 138.78 | 55.38 | 30.03 | |
| Target | |||||||||
|
Nanophase Technologies Corporation
|
|
56.10% | 141.290 | n/a | -67.70 | 12.15 | 11.45 | 9.48 | |
|
Verenium Corporation
|
|
4.70% | 351.172 | n/a | -7.84 | 6.81 | 7.36 | 18.58 | |
|
Potash Corp./Saskatchewan (USA)
|
|
n/a | 28,118.243 | 36.50 | 27.42 | 6.27 | 6.12 | 6.19 | |
|
Technip (ADR)
|
|
n/a | 8,451.634 | 24.26 | n/a | 0.85 | n/a | n/a | |
|
Nortel Networks Corporation (USA)
|
|
n/a | 7,466.913 | n/a | 29.38 | 0.66 | 0.65 | 201.81 | |
|
Huntsman Corporation
|
|
n/a | 5,803.213 | n/a | 19.75 | 0.58 | 0.60 | 3.97 | |
|
NOVA Chemicals Corporation (USA)
|
|
n/a | 3,045.995 | n/a | 10.99 | 0.47 | 0.46 | 3.45 | |
|
Empresas ICA SA (ADR)
|
|
n/a | 2,392.478 | 37.45 | n/a | 1.29 | 1.14 | 2.71 | |
|
Rockwood Holdings, Inc.
|
|
n/a | 2,329.547 | 11.69 | 17.31 | 0.75 | 0.71 | n/a | |
|
CHC Helicopter Corporation (USA)
|
|
n/a | 1,630.963 | 52.61 | 18.44 | 1.51 | 1.29 | 3.62 | |
|
American Commercial Lines Inc.
|
|
n/a | 1,328.882 | 19.49 | 17.67 | 1.30 | 1.21 | 5.73 | |
|
Blue Coat Systems, Inc.
|
|
n/a | 1,317.913 | n/a | 63.53 | 6.47 | 4.46 | 17.26 | |
|
Aspen Technology, Inc.
|
|
n/a | 1,246.431 | 47.13 | 20.10 | 3.89 | 3.77 | 14.40 | |
|
EnPro Industries, Inc.
|
|
n/a | 895.364 | n/a | 11.42 | 0.92 | n/a | 4.42 | |
|
Stillwater Mining Company
|
|
n/a | 862.260 | 141.48 | 482.50 | 1.30 | 1.27 | 1.67 | |
|
CRA International, Inc.
|
|
n/a | 564.409 | 19.62 | 19.01 | 1.55 | 1.47 | 5.12 | |
|
Trimas Corporation
|
|
n/a | 421.962 | n/a | 13.35 | 0.40 | 0.39 | n/a | |
|
First Consulting Group, Inc.
|
|
n/a | 269.570 | 14.97 | 16.65 | 0.96 | 0.89 | 2.59 | |
|
Hill International Inc.
|
|
n/a | 187.312 | 17.24 | 18.22 | 0.75 | 0.66 | 8.88 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Wal-Mart Stores, Inc.
|
|
15.00% | 176,235.594 | 14.25 | 14.16 | 0.49 | 0.47 | 3.70 | |
|
sanofi-aventis (ADR)
|
|
n/a | 116,041.327 | 21.97 | 11.99 | 2.87 | 3.01 | n/a | |
|
Sally Beauty Holdings, Inc.
|
|
n/a | 1,503.840 | 25.80 | 28.66 | 0.61 | 0.60 | n/a | |
|
99 Cents Only Stores
|
|
n/a | 752.313 | 69.21 | 38.29 | 0.66 | 0.62 | 1.44 | |
|
Helen of Troy Limited
|
|
n/a | 601.450 | 11.24 | 10.41 | 0.93 | 0.90 | 5.65 | |
|
Prestige Brands Holdings, Inc.
|
|
n/a | 533.535 | 14.76 | 14.09 | 1.66 | 1.59 | n/a | |
|
Fred's, Inc.
|
|
n/a | 418.061 | 16.32 | 14.50 | 0.23 | 0.23 | 1.11 | |
|
United-Guardian, Inc.
|
|
n/a | 50.206 | 14.95 | n/a | 3.71 | n/a | 3.65 | |
|
AMCON Distributing Co.
|
|
n/a | 15.285 | 8.52 | n/a | 0.02 | n/a | n/a | |
|
Synergy Brands, Inc.
|
|
n/a | 8.183 | n/a | n/a | 0.10 | n/a | 1.26 | |
| Target | |||||||||
|
HONDA MOTOR CO., LTD. (ADR)
|
|
n/a | 60,435.350 | 12.02 | 11.23 | 0.65 | 0.59 | 1.52 | |
|
Shire plc (ADR)
|
|
n/a | 12,860.217 | n/a | 34.83 | 6.27 | 5.96 | n/a | |
|
Sinopec Shanghai Petrochemical Co. (ADR)
|
|
n/a | 4,967.280 | 14.24 | 21.25 | 0.70 | 0.76 | 1.80 | |
|
Braskem S.A. (ADR)
|
|
n/a | 3,150.949 | 13.35 | 32.91 | 0.43 | 0.25 | 1.12 | |
|
NOVA Chemicals Corporation (USA)
|
|
n/a | 3,045.995 | n/a | 10.99 | 0.47 | 0.46 | 3.45 | |
|
Corporate Express N.V. (ADR)
|
|
n/a | 1,967.313 | 15.18 | n/a | 0.23 | n/a | n/a | |
|
UAP Holdings Corp.
|
|
n/a | 1,523.965 | 24.26 | 16.47 | 0.50 | n/a | 9.64 | |
|
A. Schulman, Inc.
|
|
n/a | 532.886 | 24.70 | 23.57 | 0.31 | 0.31 | 1.32 | |
|
American Vanguard Corp.
|
|
n/a | 470.797 | 30.62 | 27.30 | 2.39 | 2.24 | 9.87 | |
|
MetroGAS S.A. (ADR)
|
|
n/a | 248.159 | 49.66 | n/a | 0.86 | n/a | 0.78 | |
|
FinishMaster, Inc.
|
|
n/a | 242.165 | 11.78 | n/a | 0.53 | n/a | 5.60 | |
|
Plug Power Inc.
|
|
n/a | 240.842 | n/a | -4.67 | 25.54 | 17.07 | 1.15 | |
|
Applied Digital Solutions, Inc.
|
|
n/a | 66.922 | n/a | n/a | 0.54 | n/a | n/a | |
|
LANXESS AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Berkshire Hathaway Inc.
|
|
n/a | 185,674.793 | 15.38 | n/a | 1.66 | n/a | 2.24 | |
|
Wal-Mart Stores, Inc.
|
|
n/a | 176,235.594 | 14.25 | 14.16 | 0.49 | 0.47 | 3.70 | |
| Target | |||||||||
|
Royal Dutch Shell plc (ADR)
|
|
n/a | 260,977.639 | 9.60 | n/a | 0.82 | n/a | 2.43 | |
|
TOTAL S.A. (ADR)
|
|
n/a | 175,823.241 | 11.48 | 11.03 | 0.99 | 0.94 | 3.27 | |
|
DaimlerChrysler AG (USA)
|
|
n/a | 93,522.043 | 14.04 | 14.93 | 0.56 | 0.49 | 1.97 | |
|
China Petroleum & Chemical Corp. (ADR)
|
|
n/a | 92,511.502 | 10.18 | 11.61 | 0.61 | 0.49 | 2.54 | |
|
Statoil ASA (ADR)
|
|
n/a | 68,334.633 | 10.39 | 12.31 | 0.94 | 0.90 | 4.94 | |
|
RWE AG (ADR)
|
|
n/a | 63,298.683 | 9.68 | 14.85 | 1.09 | 0.96 | n/a | |
|
Norsk Hydro ASA (ADR)
|
|
n/a | 50,200.535 | 17.36 | 15.09 | 1.54 | 1.68 | 2.91 | |
|
The Dow Chemical Company
|
|
n/a | 39,883.473 | 11.40 | 10.85 | 0.79 | 0.79 | 2.73 | |
|
Sasol Limited (ADR)
|
|
n/a | 26,533.487 | 17.30 | 10.67 | 2.72 | 2.03 | 3.37 | |
|
Akzo Nobel N.V. (ADR)
|
|
n/a | 21,566.702 | 14.93 | 14.86 | 1.32 | 1.49 | 4.63 | |
|
Shire plc (ADR)
|
|
n/a | 12,860.217 | n/a | 34.83 | 6.27 | 5.96 | n/a | |
|
Solvay S.A. (ADR)
|
|
n/a | 12,027.560 | 12.32 | n/a | 0.93 | n/a | 3.48 | |
|
Huntsman Corporation
|
|
n/a | 5,803.213 | n/a | 19.75 | 0.58 | 0.60 | 3.97 | |
|
Sinopec Shanghai Petrochemical Co. (ADR)
|
|
n/a | 4,967.280 | 14.24 | 21.25 | 0.70 | 0.76 | 1.80 | |
|
Braskem S.A. (ADR)
|
|
n/a | 3,150.949 | 13.35 | 32.91 | 0.43 | 0.25 | 1.12 | |
|
NOVA Chemicals Corporation (USA)
|
|
n/a | 3,045.995 | n/a | 10.99 | 0.47 | 0.46 | 3.45 | |
|
Corporate Express N.V. (ADR)
|
|
n/a | 1,967.313 | 15.18 | n/a | 0.23 | n/a | n/a | |
|
UAP Holdings Corp.
|
|
n/a | 1,523.965 | 24.26 | 16.47 | 0.50 | n/a | 9.64 | |
|
A. Schulman, Inc.
|
|
n/a | 532.886 | 24.70 | 23.57 | 0.31 | 0.31 | 1.32 | |
|
Ballard Power Systems Inc. (USA)
|
|
n/a | 511.087 | n/a | -8.94 | 10.20 | 9.80 | 2.40 | |
|
American Vanguard Corp.
|
|
n/a | 470.797 | 30.62 | 27.30 | 2.39 | 2.24 | 9.87 | |
|
Verenium Corporation
|
|
n/a | 351.172 | n/a | -7.84 | 6.81 | 7.36 | 18.58 | |
|
MetroGAS S.A. (ADR)
|
|
n/a | 248.159 | 49.66 | n/a | 0.86 | n/a | 0.78 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 76,476.0 | 78,701.6 | 155,177.6 |
|
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 76,476.0 | 78,701.6 | 155,177.6 |
|
Cost of Revenue
|
36,686.0 | 56,585.2 | 93,271.2 |
|
SG&A Expense
|
24,340.0 | 8,940.3 | 33,280.3 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
0.0 | 1,897.9 | 1,897.9 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 1,457.9 | 1,457.9 |
| Total Expenses | 61,026.0 | 68,881.3 | 129,907.3 |
|
Operating Income
|
15,450.0 | 9,820.3 | 25,270.3 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-1,304.0 | -697.9 | -2,001.9 |
|
Other, Net
|
564.0 | 0.0 | 564.0 |
| Income Before Taxes | 14,710.0 | 9,232.7 | 23,942.7 |
| Income Taxes | 4,370.0 | 4,121.2 | 8,491.2 |
| Income After Taxes | 10,340.0 | 5,111.5 | 15,451.5 |
| Minority Interest (IS) | 0.0 | -417.9 | -417.9 |
|
Net Income - Excl. Xord. Items
|
10,340.0 | 4,693.6 | 15,033.6 |
|
Net Income - Incl. Xord. Items
|
10,340.0 | 4,693.6 | 15,033.6 |
| Preferred Dividends | -161.0 | 0.0 | -161.0 |
|
Income Avail. to Common
|
10,179.0 | 4,693.6 | 14,872.6 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
2,815.8 | 492.0 | 3,307.8 |
|
Basic EPS - Excl. Xord. Items
|
3.62 | 9.54 | 4.54 |
|
Basic EPS - Incl. Xord. Items
|
3.62 | 9.54 | 4.54 |
| Full Dilution Adjustment | 122.0 | 0.0 | 122.0 |
| Fully Diluted Shares Outstanding | 3,377.3 | 492.0 | 3,869.3 |
|
F.D. EPS - Excl. Xord. Items
|
3.01 | 9.54 | 3.89 |
|
F.D. EPS - Incl. Xord. Items
|
3.01 | 9.54 | 3.89 |
| Dividends Per Common Share | 1.28 | 4.14 | 5.42 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
5,354.0 | 1,012.4 | 6,366.4 |
|
ST Investments
|
202.0 | 110.3 | 312.3 |
|
Accounts Receivable
|
6,629.0 | 16,377.3 | 23,006.3 |
|
Inventory
|
6,819.0 | 9,006.5 | 15,825.5 |
|
Prepayments and Advances
|
3,300.0 | 0.0 | 3,300.0 |
|
Other Current Assets
|
1,727.0 | 0.0 | 1,727.0 |
|
Current Assets
|
24,031.0 | 26,506.5 | 50,537.5 |
|
PPE
|
34,721.0 | 65,194.5 | 99,915.5 |
|
Accum D&A
|
-15,181.0 | -44,783.0 | -59,964.0 |
|
PPE, Net
|
19,540.0 | 20,411.6 | 39,951.6 |
| Goodwill & Intangibles | 90,178.0 | 11,857.4 | 102,035.4 |
| Long Term Investments | 0.0 | 2,787.5 | 2,787.5 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
4,265.0 | 3,004.0 | 7,269.0 |
| Total Assets | 138,014.0 | 64,567.0 | 202,581.0 |
| Liabilities | |||
| Accounts Payable | 5,710.0 | 5,872.9 | 11,582.9 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 9,586.0 | 0.0 | 9,586.0 |
|
ST Debt
|
0.0 | 82.8 | 82.8 |
|
Curr Port of LTD & Cap Lease Oblg
|
12,039.0 | 4,526.7 | 16,565.7 |
| Other (Current) Liabilities | 3,382.0 | 8,279.7 | 11,661.7 |
|
Current Liab.
|
30,717.0 | 18,762.0 | 49,479.0 |
|
LT Debt
|
23,375.0 | 9,265.8 | 32,640.8 |
|
Total LT Debt
|
23,375.0 | 9,265.8 | 32,640.8 |
| Deferred Taxes | 12,015.0 | 2,517.1 | 14,532.1 |
|
Other LT Liab.
|
5,147.0 | 7,430.0 | 12,577.0 |
|
Total Liabilities
|
71,254.0 | 37,975.0 | 109,229.0 |
| Shareholders Equity | |||
| Redeemable Preferred | 1,406.0 | 0.0 | 1,406.0 |
| Common Stock | 3,990.0 | 1,732.3 | 5,722.3 |
| Additional Paid in Capital | 59,030.0 | 4,369.5 | 63,399.5 |
| Retained Earnings | 41,797.0 | 19,030.9 | 60,827.9 |
| Treasure Stock | -38,772.0 | 0.0 | -38,772.0 |
| Other Equity | 617.0 | 1,459.2 | 2,076.2 |
| ESOP Debt Guarantee | -1,308.0 | 0.0 | -1,308.0 |
|
Total Equity
|
66,760.0 | 26,592.0 | 93,352.0 |
|
Total Liab. & Equity
|
138,014.0 | 64,567.0 | 202,581.0 |
|
Shares Outstanding
|
3,131.9 | 490.5 | 3,622.4 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 10,340.0 | 4,695.0 | 15,035.0 |
| CF Depreciation | 3,130.0 | 4,391.5 | 7,521.5 |
| CF Deferred Taxes | 253.0 | 0.0 | 253.0 |
| Other Non-Cash Items | 279.0 | 0.0 | 279.0 |
| Change in Working Capital | -567.0 | -144.8 | -711.8 |
| Total Cash From Operating Activities | 13,435.0 | 8,941.7 | 22,376.7 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -2,945.0 | -3,426.1 | -6,371.1 |
| Other Investing Cash Flows | 462.0 | 943.4 | 1,405.4 |
| Total Cash From Investing Activities | -2,483.0 | -2,482.7 | -4,965.7 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -4,209.0 | -2,012.3 | -6,221.3 |
| Purchase Or Sale of Stock | -4,079.0 | -99.3 | -4,178.3 |
| Purchase and Retirement of Debt | -4,190.0 | -2,264.7 | -6,454.7 |
| Other Financing Cash Flow | 0.0 | -300.7 | -300.7 |
| Total Cash From Financing Activities | -12,478.0 | -5,970.8 | -18,448.8 |
| Exchange Rate Effects | 187.0 | -41.4 | 145.6 |
| Net Change in Cash | -1,339.0 | 446.9 | -892.1 |
| Cash Taxes Paid | 4,116.0 | 3,765.4 | 7,881.4 |
| Cash Interest Paid | 1,330.0 | 440.0 | 1,770.0 |